Our Team

Ron Seidel is co-founder and CEO of Crosslink Therapeutics and co-inventor of its technologies. Prior to Crosslink, Dr. Seidel was a co-founder/co-inventor of Cue Biopharma (NASDAQ: CUE).  At Cue, Dr. Seidel served as EVP and head of R&D with oversight of daily company operations integrating R&D and intellectual property development strategy with operational capabilities and scientific direction. Prior to Cue, Dr. Seidel was a Research Assistant Professor of Biochemistry and Associate Director of the Macromolecular Therapeutic Development Facility (MTDF) at the Albert Einstein College of Medicine. Dr. Seidel holds a B.S. and Ph.D. in Biochemistry/Structural Biology from the University of Georgia.

Rodolfo Chaparro is co-founder and scientific advisor of Crosslink Therapeutics and co-inventor of its technologies. Dr. Chaparro is co-founder and CEO of Kobuk therapeutics.  Prior to that he was a co-founder/co-inventor of Cue Biopharma (NASDAQ: CUE).  At Cue, Dr. Chaparro served as EVP and head of immunology, being responsible for the Company’s immuno-oncology and autoimmunity research programs as well as its preclinical and early clinical development. Prior to Cue Biopharma, Dr. Chaparro was a research faculty member in the Department of Biochemistry and MTDF at the Albert Einstein College of Medicine.  Dr. Chaparro holds a B.S. in Biology from the University of California at Irvine and a Ph.D. in immunology from Stanford University.

John Ross is Vice President of biologics discovery and preclinical development at Crosslink therapeutics.  Prior to joining Crosslink, Dr. Ross was VP of Protein Therapeutics and co-inventor of key technologies at Cue Biopharma.  Prior to Cue, Dr. Ross had leadership roles in Protein Chemistry and Proteomics, and preclinical development at Wyeth, Aileron Therapeutics, and Permeon Biologics. John’s academic experience includes a B.S. from the University of Michigan, a Ph.D. degree from the Medical College of Ohio, and a postdoctoral position at Harvard University in the laboratory of Brian Dynlacht.